Abbildung 58: EUROPA-Studie - Ergebnisse
As prof. Willem Remme, EUROPA Chairman added: "The EUROPA results are profound. Cardiovascular deaths, myocardial infarction and heart failure were all significantly reduced in patients given treatment based on ACE inhibitor perindopril, in addition to standard optimal therapy including aspirin, statins and ß -blockers". In this largest and longest trial of stable CAD patients, perindopril 8 mg once daily reduced significantly: - CV mortality, non-fatal MI and cardiac arrest by 20 % - CV mortality and non fatal MI by 19 % - Fatal and non fatal MI by 24 % - Heart failure by 39 %